摘要
背景:CCAAT /增强子结合蛋白(C / EBPs)在不同发育阶段形成一系列转录因子,调节许多基因在多种细胞/组织/器官中的表达。通过它们与其同源DNA元件结合的能力和蛋白质 - 蛋白质相互作用,C / EBPs在生理和病理条件下调节多种功能,包括细胞分化,代谢和免疫应答,如建立血液谱系,维持正常生殖功能和恶性肿瘤的发展。 目的:本综述集中在C / EBP基因在血液恶性肿瘤和妇科器官和疾病中的作用和表观遗传学改变。对涉及C / EBP功能和调控的分子途径的新研究结果进行了回顾和分析。还讨论了这些发现的潜在治疗价值。 结论:C / EBP突变及其破坏野生型C / EBP肿瘤抑制活性的血液恶性肿瘤不同于C / EBP突变在妇科癌症中并不常见,引起了一些疑问, C / EBPs可能在妇科癌症中具有肿瘤抑制活性。然而,这个概念不能排除C / EBP的下调或DNA甲基化沉默的表观遗传学沉默可能有助于妇科恶性肿瘤发展的可能性。
关键词: CCAAT /增强子结合蛋白,C / EBP,妇科癌症,血液恶性肿瘤,高甲基化,表观遗传调节异常
图形摘要
Current Drug Targets
Title:CEBP Epigenetic Dysregulation as a Drug Target for the Treatment of Hematologic and Gynecologic Malignancies
Volume: 18 Issue: 10
关键词: CCAAT /增强子结合蛋白,C / EBP,妇科癌症,血液恶性肿瘤,高甲基化,表观遗传调节异常
摘要: Background: The CCAAT/enhancer binding proteins (C/EBPs) form a family of transcription factors regulating many genes’ expression in a variety of cells/tissues/organs at different developmental stages. With their capability of binding to their cognate DNA elements and through protein-protein interactions, C/EBPs modulate diverse functions including cell differentiation, metabolism, and immune response, under both physiological and pathological conditions such as the establishment of hematological lineages, the maintenance of normal reproductive function, and the development of malignancies.
Objectives: This review concentrates on the role(s) and epigenetic alterations of C/EBP genes in hematologic malignancies and gynecologic organs and disorders. New research findings on molecular pathways involved in C/EBP function and regulation are reviewed and analyzed. The potential therapeutic values of these findings are also discussed. Conclusion: Unlike in hematologic malignancies in which C/EBP mutations and their disruption of wild type C/EBP tumor suppressive activities have been well documented, mutation of C/EBP does not appear to be a common event in gynecologic cancers, raising some doubt if C/EBPs may have tumor suppressor activity in gynecologic cancers. However, this notion could not exclude the possibility that downregulation or DNA methylation-meditated epigenetic silencing of C/EBPs may contribute to the development of gynecologic malignancies.Export Options
About this article
Cite this article as:
CEBP Epigenetic Dysregulation as a Drug Target for the Treatment of Hematologic and Gynecologic Malignancies, Current Drug Targets 2017; 18 (10) . https://dx.doi.org/10.2174/1389450117666161228160455
DOI https://dx.doi.org/10.2174/1389450117666161228160455 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Expression and Function of Organic Cation and Anion Transporters (SLC22 Family) in the CNS
Current Pharmaceutical Design The Optimal Treatment of Thyroid Gland Function Disturbances During Pregnancy
Current Pharmaceutical Biotechnology Aliphatic and Aromatic Oxidations, Epoxidation and S-Oxidation of Prodrugs that Yield Active Drug Metabolites
Current Medicinal Chemistry Sinonasal Carcinoma: Updated Phenotypic and Molecular Characterization
Current Cancer Therapy Reviews Modulation of Expression and Activity of ABC Transporters by the Phytoestrogen Genistein. Impact on Drug Disposition
Current Medicinal Chemistry Hypomethylation and Activation of Syncytin-1 Gene in Endometriotic Tissue
Current Pharmaceutical Design Recent Developments of Steroid Sulfatase Inhibitors as Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Recent Developments of Flavonoids with Various Activities
Current Topics in Medicinal Chemistry The Carnitine Transporter Network: Interactions with Drugs
Current Chemical Biology Recent Advances in New Discovered Molecular Targets in Testicular Germ Cell Tumors
Current Medicinal Chemistry Fungal Proteins with Antiproliferative and Anticancer Activities
Protein & Peptide Letters The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets Connexins as Precocious Markers and Molecular Targets for Chemical and Pharmacological Agents in Carcinogenesis
Current Medicinal Chemistry Cadmium and Its Epigenetic Effects
Current Medicinal Chemistry Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Membrane Fusion Mediated Targeted Cytosolic Drug Delivery Through scFv Engineered Sendai Viral Envelopes
Current Molecular Medicine An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs
Current Topics in Medicinal Chemistry Kinetic Evaluation of Anti-tumor Chlorambucil Release from O-stearoyl Mannose PLGA Nanoparticles
Current Nanomedicine Mycotoxins Levels in Human Milk: A Menace to Infants and Children Health
Current Nutrition & Food Science Dihydrofolate Reductase Gene Variations in Susceptibility to Disease and Treatment Outcomes
Current Genomics